Immune System Genetic Testing: Technical Overview, Methods, and Applications

Immune system genetic testing is an advanced molecular diagnostic approach that analyzes genes governing immune function to identify inherited variants associated with immunodeficiency, autoimmune susceptibility, transplant compatibility, and variable drug response. This comprehensive technical guide explains the scope of immune gene testing, acceptable sample types, core testing items, analytical methods, and clinical applications. All testing described here can be performed by accredited third-party laboratories or clinical molecular laboratories conforming to international standards such as ISO 15189 and ISO/IEC 17025.

Technical Overview

Immune system genetic testing refers to the laboratory analysis of genomic variants in genes that regulate human immune function, including genes governing innate immunity, adaptive immunity, cytokine signaling, complement activation, and human leukocyte antigen (HLA) presentation. By sequencing and genotyping these regions, clinicians and researchers can identify germline mutations and polymorphisms associated with inborn errors of immunity, autoimmune disease susceptibility, allograft compatibility, and individualized drug response.

The human immune system is controlled by hundreds of genes distributed across the genome, with a particularly dense and highly polymorphic cluster located in the major histocompatibility complex (MHC) region on chromosome 6p21.3. Pathogenic variants in key immune genes, such as RAG1/RAG2 (V(D)J recombination), IL2RG (cytokine receptor signaling), ADA (purine salvage metabolism), STAT3 (signal transduction), BTK (B-cell development), and the HLA class I and II loci, can produce clinical phenotypes ranging from severe combined immunodeficiency (SCID) in infancy to chronic autoimmune inflammation in adults. Molecular testing provides a definitive etiological explanation for recurrent infections, unexplained inflammation, lymphopenia, abnormal immunoglobulin levels, and early-onset autoimmunity.

Testing is typically performed in accredited third-party laboratories or hospital molecular diagnostics departments operating under quality management systems conforming to ISO 15189 (requirements for quality and competence in medical laboratories) and ISO/IEC 17025 (general requirements for the competence of testing and calibration laboratories). Pre-examination procedures for sample collection, transport, and nucleic acid preservation follow standardized molecular diagnostics workflows, and bioinformatics interpretation is aligned with internationally recognized clinical sequence variant interpretation frameworks. Biobanking of residual specimens, where applicable, is managed in accordance with ISO 20387 and relevant GB/T national standards.

Testing Samples

Immune system genetic testing is performed on genomic DNA extracted from a variety of biological specimens. The choice of sample type depends on the clinical scenario, the age of the individual, and the required test methodology. General requirements for each specimen type are summarized below.

Whole Blood (EDTA Anticoagulated)

Peripheral whole blood collected in EDTA tubes is the preferred and most widely used specimen. A volume of 2–5 mL is generally sufficient for adults, with 0.5–2 mL acceptable for infants and neonates. Heparinized blood is not recommended because heparin can inhibit downstream polymerase activity during amplification. Samples should be transported at 2–8 °C and processed within 72 hours of collection to ensure genomic DNA integrity. The extracted DNA should meet defined acceptance criteria, typically a concentration of at least 20–50 ng/μL, a total yield of at least 1–2 μg, and an A260/A280 absorbance ratio between 1.8 and 2.0.

Buccal Swabs and Saliva

Buccal swabs and saliva collection kits provide non-invasive alternatives when venipuncture is impractical, such as for large-scale carrier screening, family segregation studies, or follow-up testing of relatives. At least two swabs rubbed firmly against the inner cheek surface are required. Because oral specimens may contain lower quantities of human DNA and potential microbial contamination, they are primarily suited to targeted genotyping or confirmation testing rather than comprehensive sequencing panels.

Dried Blood Spots

Dried blood spot (DBS) cards, already established in newborn screening programs for SCID markers such as T-cell receptor excision circles (TRECs), can also serve as a DNA source for confirmatory genetic testing. DBS specimens are stable at ambient temperature for extended periods, simplify logistics, and require only a small blood volume, making them valuable for retrospective testing of archived newborn samples and for use in regions with limited cold-chain infrastructure.

Prenatal and Other Specimen Types

For families with a previously identified pathogenic variant, prenatal diagnosis can be performed on chorionic villus samples collected at 10–13 weeks of gestation or amniotic fluid collected after 15 weeks. Cord blood obtained at delivery may also be used when an affected sibling requires early confirmation. Extracted genomic DNA, formalin-fixed paraffin-embedded tissue, and cultured cell pellets are accepted by some laboratories for specific targeted assays, subject to DNA quality verification.

Testing Items

Testing items are organized into several clinical modules. Laboratories typically offer these modules individually or as a combined comprehensive immune gene panel depending on the clinical indication.

HLA Genotyping

High-resolution genotyping of HLA class I loci (HLA-A, HLA-B, HLA-C) and class II loci (HLA-DRB1, HLA-DQB1, HLA-DPB1) is performed for transplant matching, disease association studies, and drug hypersensitivity prediction. Typical disease association markers include:

• HLA-B*27 — association with ankylosing spondylitis and axial spondyloarthritis
• HLA-B*57:01 — screening for hypersensitivity to certain antiretroviral therapy
• HLA-B*15:02 and HLA-A*31:01 — risk of severe cutaneous adverse reactions to certain anticonvulsants
• HLA-DQ2/DQ8 — association with celiac disease susceptibility
• HLA-DRB1 alleles — associations with rheumatoid arthritis and type 1 diabetes susceptibility

Inborn Errors of Immunity (Primary Immunodeficiency) Gene Panels

Comprehensive panels cover genes responsible for combined immunodeficiencies, predominantly antibody deficiencies, immune dysregulation syndromes, phagocyte defects, complement deficiencies, and autoinflammatory disorders. Representative gene categories include:

• SCID-associated genes: IL2RG, JAK3, RAG1, RAG2, ADA, DCLRE1C, PTPRC, CD3D, CD3E
• Agammaglobulinemia and antibody deficiency genes: BTK, IGHM, CD79A, CD79B, TCF3
• Immune dysregulation genes: FOXP3, IL2RA, CTLA4, LRBA, STAT3, AIRE
• Phagocyte defect genes: CYBB, NCF1, CYBA, LYST, WAS
• Complement pathway genes: C1QA, C1QB, C2, C4A, C4B, C5, C6, C7, C8A, C8B, C9, CFH, CFI, CFD, MASP2
• Innate immunity and autoinflammatory genes: MEFV, NLRP3, TNFRSF1A, MVK, TLR3, UNC93B1

Autoimmune Susceptibility and Immune Regulation Genes

Testing evaluates risk-associated variants in immune regulatory genes and non-HLA loci, including PTPN22, CTLA4, PADI4, STAT4, IRF5, TNFAIP3, and promoter polymorphisms of cytokine genes such as TNF, IL1B, IL6, IL10, and IFNG. These results are interpreted as probabilistic risk modifiers rather than deterministic predictions and are typically used in combination with clinical findings and serological markers.

Innate Immunity Function Polymorphisms

Functional polymorphisms affecting innate immune recognition and opsonization are analyzed for individuals with recurrent or severe infections. Common targets include mannose-binding lectin (MBL2) variants, Toll-like receptor polymorphisms (TLR2, TLR4, TLR5), and surfactant protein variants, which modulate susceptibility to bacterial, viral, and fungal pathogens.

Immune-Related Pharmacogenomic Markers

Genotyping of drug-metabolism and drug-response genes supports personalized dosing of immunosuppressive and immunomodulatory therapies:

• TPMT and NUDT15 — thiopurine metabolism, guiding azathioprine and 6-mercaptopurine dosing
• CYP3A5 and ABCB1 — tacrolimus and cyclosporine dosing optimization
• MTHFR — methotrexate tolerance assessment
• IFNL3/IFNL4 (IL28B) — interferon response prediction

Testing Methods

A range of validated molecular techniques is employed depending on the scope of the requested analysis, the required resolution, and the sample type. All methods are performed under documented quality control procedures with defined analytical performance characteristics.

Next-Generation Sequencing (NGS)

Targeted NGS gene panels are the current mainstay for comprehensive immune gene analysis. Hybridization-capture or multiplex amplicon libraries are sequenced on short-read platforms, typically achieving mean target coverage of at least 100× with more than 98% of target bases covered at a depth of at least 20×. NGS panels can detect single nucleotide variants (SNVs), small insertions and deletions (indels), and selected copy number variations (CNVs) within captured regions. For genetically heterogeneous or atypical presentations, whole-exome sequencing (WES) and whole-genome sequencing (WGS) extend the analytical scope beyond curated immune gene lists, supported by trio analysis and segregation studies for variant confirmation.

Sanger Sequencing

Sanger sequencing remains the reference method for confirmation of variants identified by NGS and for single-gene testing when a specific diagnosis is strongly suspected based on family history or clinical phenotype. It delivers high-quality bidirectional reads of individual exons or amplicons with analytical sensitivity above 99% for heterozygous SNVs within the sequenced region.

PCR-Based HLA Typing

HLA genotyping is performed using polymerase chain reaction with sequence-specific primers (PCR-SSP) for rapid low-resolution screening, reverse dot-blot or Luminex-based sequence-specific oligonucleotide probing (PCR-SSO) for intermediate resolution, and NGS-based HLA typing for unambiguous high-resolution (four-field or greater) allele assignment. NGS-based phasing resolves heterozygous ambiguity in the highly polymorphic HLA loci, which is essential for hematopoietic stem cell matching and antibody-mediated risk assessment in solid organ transplantation.

Quantitative Real-Time PCR

Allele-specific qPCR and TaqMan genotyping assays provide rapid, cost-effective detection of predefined variants, including HLA-B*27 screening, thiopurine pharmacogenomic markers, and confirmation of familial variants in cascade testing of relatives. Real-time PCR is also used for relative gene expression analysis when immune dysfunction assessment extends to transcript-level investigation.

Multiplex Ligation-Dependent Probe Amplification (MLPA)

MLPA detects exon-level deletions and duplications that sequencing alone may miss. It is particularly important for complement component genes (C4A/C4B copy number), LRBA, CTLA4, and other loci where partial gene deletions are established disease mechanisms. Chromosomal microarray or read-depth CNV calling from NGS data provides genome-wide complementary detection.

Bioinformatics Analysis and Variant Interpretation

Sequencing data undergo standardized processing: demultiplexing, quality trimming, alignment to the GRCh38 reference genome, duplicate marking, base quality recalibration, and variant calling. Candidate variants are annotated against curated clinical variant databases, population frequency resources, and in-silico pathogenicity prediction tools. Variants are classified into pathogenic, likely pathogenic, uncertain significance (VUS), likely benign, or benign categories following internationally recognized five-tier clinical variant interpretation guidelines, and reports are reviewed by qualified molecular genetics professionals.

Applications

Clinical Diagnosis of Immune Disorders

Genetic confirmation of inborn errors of immunity establishes a definitive diagnosis, ends the diagnostic odyssey, guides selection of curative treatments such as hematopoietic stem cell transplantation or enzyme replacement, and informs prognosis and infection prophylaxis strategies.

Transplantation Matching

High-resolution HLA genotyping supports donor selection for hematopoietic stem cell transplantation and solid organ transplantation, contributes to donor-specific antibody risk assessment, and reduces the probability of graft-versus-host disease and graft rejection.

Personalized Immunosuppressive Therapy

Pharmacogenomic results enable dose individualization of thiopurines, tacrolimus, and methotrexate, reducing the risk of myelosuppression, hepatotoxicity, and other serious adverse drug reactions in transplant recipients and patients with autoimmune disease.

Newborn Screening Follow-Up

Abnormal TREC or lymphocyte subset results from newborn screening programs are confirmed through targeted genetic testing of SCID-associated genes, enabling early intervention before life-threatening infections occur.

Genetic Counseling and Family Planning

Identification of a pathogenic variant allows cascade testing of family members, carrier status determination for autosomal and X-linked immune disorders, and access to prenatal diagnosis or preimplantation genetic testing in subsequent pregnancies.

Biomedical and Pharmaceutical Research

Anonymized genetic data contribute to research on immune disease mechanisms, genotype-phenotype correlations, population immunogenetics, and the development of immunotherapies and vaccines.

FAQ

What is immune system genetic testing?

Immune system genetic testing is a molecular laboratory analysis that examines genes controlling immune function to identify inherited or acquired variants associated with immunodeficiency, autoimmune disease susceptibility, HLA-related conditions, and individual variation in response to immune-related medications.

Who should consider immune system genetic testing?

Candidates include infants and children with recurrent, severe, or opportunistic infections; individuals with early-onset autoimmunity or unexplained lymphopenia and hypogammaglobulinemia; patients with a family history of primary immunodeficiency; transplant candidates and donors requiring HLA typing; and patients beginning immunosuppressive therapy where pharmacogenomic dosing is clinically indicated.

What sample is required and how much does it hurt to collect?

The standard sample is 2–5 mL of venous blood drawn into an EDTA tube, collected by routine venipuncture. Non-invasive buccal swab or saliva options are available for family studies, and dried blood spots are used for newborn follow-up, so collection is minimally burdensome for all age groups.

How accurate is the testing?

In accredited laboratories, Sanger sequencing and validated NGS workflows achieve analytical sensitivity and specificity exceeding 99% for SNVs and small indels within covered regions. HLA high-resolution typing by NGS resolves ambiguous phase combinations that older methods could not. Limitations remain for variants in poorly covered regions, deep intronic variants, and certain structural rearrangements.

How long does it take to receive results?

Turnaround times vary by methodology: targeted qPCR genotyping and HLA-B*27 screening typically require 3–7 working days, HLA high-resolution typing 7–14 working days, targeted NGS panels 10–20 working days, and whole-exome or whole-genome sequencing up to 4–6 weeks including confirmation and interpretation.

Does a positive result mean I will definitely develop a disease?

No. Results fall into two categories. Pathogenic variants in monogenic immune disorder genes carry high but not always complete penetrance and require correlation with clinical and immunological findings. Susceptibility polymorphisms, by contrast, only modify statistical risk and do not determine disease outcomes on their own. Genetic counseling before and after testing is strongly recommended.

Is my genetic information kept confidential?

Yes. Accredited third-party laboratories and clinical laboratories operate under strict data governance, informed consent procedures, and privacy protection requirements consistent with ISO 15189 quality frameworks and applicable national regulations covering human genetic resources and personal health information.